Immune Response BioPharma, Inc. Press releases11 - 20 of 44 Press Releases
Feb 09, 2014
Immune Response BioPharma, Inc. Announces its Flagship Vaccine NeuroVax Granted Orphan Designation for Pediatric MS by the FDA.
Dec 25, 2013
Immune Response BioPharma Sets U.S. REMUNE Pricing Range $75-250 Per Dose with a Target of $100 or Less, Goal of $50 per dose, Once Commercial Manufacturing & Stockpiling is Secured on a Large Scale or a New Manufacturing Plant is Built.
Dec 22, 2013
Immune Response BioPharma, Inc., Announces its Plans to Develop Annual Preventative HIV/AIDS Vaccine RemuneVax IR-2020 Based on Current Mutated HIV Strain for Preventative Use.
Dec 03, 2013
Immune Response BioPharma to File Remune BLA with FDA by March 1st 2014 & Submits Fee Waiver Request, IRBP also plans to Transition the Vaccine to Preventative Use.
Nov 24, 2013
Immune Response BioPharma to Keep U.S. NeuroVax Rights for MS Expects Phase IIb Enrollment to Begin by Q2 2015.
Sep 03, 2013
Immune Response BioPharma, Inc. to Seek Fast Track & Orphan Designation of NeuroVax for SPMS to Expand Novel use of MS Vaccine Treatment
Aug 11, 2013
Immune Response BioPharma, Inc. Posts 1st Half 2013 Results & 2nd Half 2013 Guidance on Partnering
Jul 12, 2013
Immune Response BioPharma, Inc. to Seek BLA Approval of REMUNE with EMA & Enter the Eurozone with Expansion of HIV Vaccine Marketing Authorization
Jun 18, 2013
Immune Response BioPharma, Inc., has notified the MCC of South Africa that IRBP will Seek Emergency Approval of REMUNE in S.A. as well begin stockpiling & manufacturing the HIV/AIDS vaccine once we have secured a corporate partner in the region.
Jun 08, 2013
Immune Response BioPharma, Inc. IR103 Phase II Study Results CTN 203 or IR103-111 REMUNEX Provides Maximum Effect in Patients Treated with REMUNE + Amplivax HIV/AIDS Vaccine.